Application and Research Status of <sup>125</sup>I Seeds Brachytherapy in Unresectable Pancreatic Cancer

Xinxin Duan; Liuyi Yang; Jie Zhou; Ting Xiong; Aixia Sui

doi:doi:10.11648/j.crj.20221002.14

| Peer-Reviewed

Application and Research Status of ¹²⁵I Seeds Brachytherapy in Unresectable Pancreatic Cancer

Xinxin Duan, Liuyi Yang, Jie Zhou, Ting Xiong, Aixia Sui

Published in Cancer Research Journal (Volume 10, Issue 2)

Received: 2 June 2022 Accepted: 16 June 2022 Published: 27 June 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Pancreatic cancer is a digestive system tumor with high degree of malignancy. At present, systemic chemotherapy is the main treatment method. However, due to the difficulty in early diagnosis and easy spread of pancreatic cancer, the survival cycle of patients is short and the treatment effect is poor. ¹²⁵I seed brachytherapy has obvious advantages in the treatment of malignant tumors, and has been widely used in the treatment of unresectable pancreatic cancer. Either used alone or combined with chemotherapy, the treatment of ¹²⁵I seed brachytherapy can effectively relieve pain, improve life quality and prolong survival. However, there are few reports about the application status. This article reviews the current updates of ¹²⁵I seed brachytherapy for resectable pancreatic cancer, and expounds the application status of ¹²⁵I seeds brachytherapy in combination with monotherapy chemotherapy, dual drug chemotherapy, targeted therapy, immunity therapy, palliative surgery, external radiotherapy and traditional Chinese medicine. Based on the retrospective review, future directions of research and development of brachytherapy for unresectable pancreatic cancer is also proposed, to provide better treatment care for pancreatic cancer patients. At present, there are still many problems to be solved, such as formulating the principles and standards for the application of radioactive particle implantation in the comprehensive treatment of pancreatic cancer; We will continue to standardize and optimize the operation process and distribution means of radioactive seed implantation technology, and better promote 125I radioactive seed implantation technology.

Published in	Cancer Research Journal (Volume 10, Issue 2)
DOI	10.11648/j.crj.20221002.14
Page(s)	38-45
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

125I Seeds, Brachytherapy, Advanced Pancreatic Cancer, Combination Therapy, Chemotherapy

References

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. 66: 115-132.
[2]	Ye Z, Zhuo Q, Hu Q, et al. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Redox Biol. 2021 Jan; My days of 1807.
[3]	McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21; 24 (43): 4846-4861.
[4]	Zhang Q, Zeng L, Chen Y, et al. Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterol Res Pract. 2016; 2016: 8962321.
[5]	Tao J, Yang G, Zhou W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021 Jan 13; 14 (1): 14.
[6]	Huang J M, Yu N W. Research progress of ~ ⁽¹²⁵⁾I radioactive particle therapy for cancer [J]. Isotope, 2020 01: 186-198.
[7]	Wang J, Jiang Y, Li J, et al. Intraoperative ultrasound-guided iodine-¹²⁵ seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2009 Jun 23; 28 (1): 88.
[8]	Zhongmin W, Yu L, Fenju L, et al. Clinical efficacy of CT-guided iodine-¹²⁵ seed implantation therapy in patients with advanced pancreatic cancer. Eur Radiol. 2010 Jul; 20 (7): 1786-91.
[9]	Zhang L Y, Wang Z M, Chen K M, et al. Research progress of interstitial implantation of ~ ⁽¹⁰³⁾Pd particles in the treatment of malignant tumor [J]. Journal of interventional radiology, 2009, 10: 789-792.
[10]	Wu Weixia, ZHOU Zhigang, XING Mingquan. Ct-guided ~ ⁽¹²⁵⁾I radioactive particle implantation in the treatment of unresectable pancreatic cancer: Current status and prospects [J]. Chinese journal of clinical physicians (electronic edition), 2018, 03: 181-184.
[11]	Lazarescu G R, Battista J J. Analysis of the radiobiology of ytterbium-169 and iodine-¹²⁵ permanent brachytherapy Implants. [J]. Journal of Physics in medicine and biology, 1997429.
[12]	GuX Z, Yin WB, Yu ZH. Radiation Oncology [M]. Beijing: Pecking Union Medical College Press, 2015: 222-284.
[13]	Luo M, Chen J, Zhong Z, et al. CT-guided ¹²⁵I brachytherapy combined with chemotherapy for the treatment of unresectable or locally advanced pancreatic carcinoma. Diagn Interv Radiol. 2021 Jan; 27 (1): 50 and 58.
[14]	Chen C, Wang W, Wang W, et al. Locally advanced pancreatic carcinoma with jaundice: The benefit of a sequential treatment with stenting followed by CT-Guided ¹²⁵I seeds. Eur Radiol. 2021 Sep; 31 (9): 6500-6510.
[15]	Li Hongwei. Ct-guided ~ ⁽¹²⁵⁾I particle implantation in the treatment of 90 cases of pancreatic cancer [J]. Chinese Medical Guide, 2014, 15: 154-155.
[16]	Liu Ying, RAN Linhao, Huang Xuequan. Clinical study of ¹²⁵I radioactive seeds implanted under CT guidance in the treatment of pancreatic cancer [J]. Chinese Journal of CT and MRI, 19 (2): 3.
[17]	Du Siyun, Fu Ping, GAi Baodong, Yang Dongyan. Ultrasound-guided percutaneous implantation of radioactive ¹²⁵I seeds for the treatment of abdominal cancer [J]. Chinese journal of medical ultrasound (electronic edition), 2019, 16 (2): 142-146.
[18]	Fu Ping, Xue Jianan, Gai Baodong, et al. Ultrasound-guided percutaneous puncture and implantation of ¹²⁵I radioactive particles into gastric wall for treatment of advanced pancreatic cancer [J]. Chinese Journal of Ultrasound Imaging, 2017, 26 (012): 1034-1038.
[19]	Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1; 34 (22): 2654-68.
[20]	Li Yunxia, SHEN Zhensheng. Efficacy of chemotherapy combined with radiotherapy in the treatment of advanced pancreatic cancer [J]. J Systemic Med, 2020, 4: 1-3.
[21]	Huo Liwei, Zhang Li. Therapeutic effect of gemcitabine and cisplatin combined with radioactive particle implantation on pancreatic cancer [J]. World Latest Medical Information Abstracts, 2019, 20: 166+169.
[22]	Huang S Q, Ning H F, Cui X J, et al. Clinical observation of ~ ⁽¹²⁵⁾I particle implantation combined with chemotherapy in 72 cases of unresected advanced pancreatic cancer [J]. Chin j cancer, 2020, 17: 1415-1420.
[23]	ZHONG Zhenwu, ZHONG Hui, LIU Ling, XIE Lingyan, et al. Effect of ~ ⁽¹²⁵⁾I radioactive particle implantation and postoperative combined gemcitabine chemotherapy in the treatment of advanced pancreatic cancer [J]. Chinese journal of contemporary medicine, 2018, 17: 69-71.
[24]	Heinrich S, Pestalozzi BC, Schafer M, et al. Prospective phase II trail of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable Groups of pancreatic adenocarcinoma groups from pancreatic carcinoma [J]. Chinese journal of pancreatic cancer, 2008, 26 (15): 2526-2531.
[25]	Zhou Tianyi, He Xiaohui, TAN Zhihui, et al. A meta-analysis of gemcitabine combined with cisplatin in patients with advanced pancreatic cancer [J]. Modern oncology, 2019, 14: 2546-2552.
[26]	Liu Y, Liu Y F. The clinical efficacy of ¹²⁵I seed implantation combined with GP chemotherapy in the treatment of advanced pancreatic cancer [J]. Chinese Journal of Endemic Disease Control, 2018, 06: 672.
[27]	Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1; 31 (13): 1640-8.
[28]	Hirata K, Horikoshi N, Tominaga K, et al. [Pharmacokinetics of S-1]. Gan To Kagaku Ryoho. 2006 Jun; 33 Suppl 1: 27-35. Japanese. PMID: 16897969.
[29]	LI Mingjun, WANG Wengang, QIN Yanru, et al. Clinical observation of gemcitabine combined with tegio in the treatment of advanced pancreatic cancer [J]. Chin J continuing medical education, 2016, 20: 153-155.
[30]	FuHong. Efficacy of cisplatin combined with gemcitabine in the treatment of advanced pancreatic cancer [J]. Medical Journal of Metallurgical Industry in China, 2019, 06: 719-720.
[31]	Chen Xingguang. Ultrasound-guided percutaneous implantation of ¹²⁵I radioactive seeds in the treatment of 106 cases of pancreatic cancer [J]. J general stomatology, 2019, 36: 126-127.
[32]	Hoanli. Clinical value of cT-guided ~ ⁽¹²⁵⁾I radioactive particle implantation combined with GS chemotherapy in the treatment of advanced pancreatic cancer [J]. Ningxia medical journal, 2018, 08: 717-719.
[33]	SHI Guangyong. Clinical evaluation of cT-guided ~ ⁽¹²⁵⁾I particle implantation combined with drug chemotherapy for advanced local pancreatic cancer [J]. China Pharmaceutical, 2017, 14: 50-53.
[34]	Chiorean EG, Cheung WY, Giordano G, et al. Real-world comparative effectiveness of NAb-Paclitaxel plus Gemcitabine versus FOLFIRINOX in Advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019 May 19; And 58835919850367.
[35]	Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31; 369 (18): 1691-703.
[36]	Huang Feilong, Liu Xiaofang, Huang Shengchuan, et al. Laparoscopic iodine-¹²⁵ particle implantation for the treatment of unresectable pancreatic cancer [J]. Clinical research & practice, 2018, 10: 4-6+9.
[37]	Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20; 25 (15): 1960-6.
[38]	Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15; 59 (8): 1935-40. PMID: 10213503.
[39]	Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol. 2007 Jun; 83 (3): 238-48.
[40]	Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005 Apr 15; 65 (8): 3328-35.
[41]	Szumiel I. Epidermal growth factor receptor and DNA double strand break repair: the cell's self-defence. Cell Signal. 2006 Oct; 18 (10): 1537-48.
[42]	Gao C, Wu X, Yan Y, et al. Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells. Technol Cancer Res Treat. 2016 Jun; 15 (3): 446-52.
[43]	Kirshner J, Jobling MF, Pajares MJ, et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 2006 Nov 15; 66 (22): 10861-9.
[44]	Dubrovska A, Kanamoto T, Lomnytska M, et al. TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage. Oncogene. 2005 Mar 31; 24 (14): 2289-97.
[45]	Kanamoto T, Hellman U, Heldin CH, et al. Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair. EMBO J. 2002 Mar 1; 21 (5): 1219-30.
[46]	Gandhi N, Wild AT, Chettiar ST, et al. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther. 2013 Apr; 14 (4): 347-56.
[47]	Zaidi S, McLaughlin M, Bhide SA, et al. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One. 2012; 7 (4): e35436.
[48]	Walker AJ, Alcorn SR, Narang AK, et al. Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. Curr Probl Cancer. 2013 Sep-Oct; 37 (5): 301-12.
[49]	Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar; 18 (3): 175-196.
[50]	Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27; 515 (7528): 563-7.
[51]	Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28; 366 (26): 2455-65.
[52]	Mahmood J, Shukla HD, Soman S, et al. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers (Basel). 2018 Nov 28; 10 (12): 469.
[53]	Knudsen ES, Vail P, Balaji U, et al. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clin Cancer Res. 2017 Aug 1; 23 (15): 4429-4440.
[54]	Fan YF, Qin Y, Li DG, et al. Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia. J Glob Oncol. 2018 Sep; 4: 1-4.
[55]	Huang Hongjun, JIANG Yong, Wu Baoqiang, SUN Donglin. Analysis of complications and prognosis of ¹²⁵I seed implantation in patients with unresectable advanced pancreatic cancer [J]. Journal of Hepatobiliary and Pancreatic Surgery, 2014 (26): 281-284.
[56]	Mendlovic S, Symon Z, Kundel Y, et al. [Three-dimensional conformal radiation therapy concurrent with full dose Gemcitabine for locally advanced inoperable pancreatic cancer]. Harefuah. 2008 May; 147 (5): 384-7, 480. Hebrew. PMID: 18770957.
[57]	Yu YP, Yu Q, Guo JM, et al. ⁽¹²⁵⁾I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer. Br J Radiol. 2014 Apr; Doi: 10. ¹²⁵9/ BJR. 20130641. PMID: 24625042; PMCID: PMC4067019.
[58]	Li X Q, Liu C L. The efficacy of ~ ⁽¹²⁵⁾I particle implantation combined with concurrent external radiotherapy and chemotherapy in the treatment of advanced pancreatic cancer [J]. Chinese Medical Guide, 2014, 24: 123-124.
[59]	Wang Jiangwei, Su Xiaolin, ZHAO Wan, et al. Clinical application and mechanism of Traditional Chinese medicine in the treatment of pancreatic cancer [J]. Chin J Med, 2020, 07: 31-34.
[60]	Guan Zi, Huang Xuewu, Yan Peiyu. Research progress of traditional Chinese medicine in the treatment of pancreatic cancer [J]. Sichuan traditional Chinese medicine, 2020, 04: 217-221.

Cite This Article

Plain Text BibTeX RIS

APA Style

Xinxin Duan, Liuyi Yang, Jie Zhou, Ting Xiong, Aixia Sui. (2022). Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer. Cancer Research Journal, 10(2), 38-45. https://doi.org/10.11648/j.crj.20221002.14

Copy | Download

ACS Style

Xinxin Duan; Liuyi Yang; Jie Zhou; Ting Xiong; Aixia Sui. Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer. Cancer Res. J. 2022, 10(2), 38-45. doi: 10.11648/j.crj.20221002.14

Copy | Download

AMA Style

Xinxin Duan, Liuyi Yang, Jie Zhou, Ting Xiong, Aixia Sui. Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer. Cancer Res J. 2022;10(2):38-45. doi: 10.11648/j.crj.20221002.14

Copy | Download

@article{10.11648/j.crj.20221002.14,
  author = {Xinxin Duan and Liuyi Yang and Jie Zhou and Ting Xiong and Aixia Sui},
  title = {Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer},
  journal = {Cancer Research Journal},
  volume = {10},
  number = {2},
  pages = {38-45},
  doi = {10.11648/j.crj.20221002.14},
  url = {https://doi.org/10.11648/j.crj.20221002.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221002.14},
  abstract = {Pancreatic cancer is a digestive system tumor with high degree of malignancy. At present, systemic chemotherapy is the main treatment method. However, due to the difficulty in early diagnosis and easy spread of pancreatic cancer, the survival cycle of patients is short and the treatment effect is poor. 125I seed brachytherapy has obvious advantages in the treatment of malignant tumors, and has been widely used in the treatment of unresectable pancreatic cancer. Either used alone or combined with chemotherapy, the treatment of 125I seed brachytherapy can effectively relieve pain, improve life quality and prolong survival. However, there are few reports about the application status. This article reviews the current updates of 125I seed brachytherapy for resectable pancreatic cancer, and expounds the application status of 125I seeds brachytherapy in combination with monotherapy chemotherapy, dual drug chemotherapy, targeted therapy, immunity therapy, palliative surgery, external radiotherapy and traditional Chinese medicine. Based on the retrospective review, future directions of research and development of brachytherapy for unresectable pancreatic cancer is also proposed, to provide better treatment care for pancreatic cancer patients. At present, there are still many problems to be solved, such as formulating the principles and standards for the application of radioactive particle implantation in the comprehensive treatment of pancreatic cancer; We will continue to standardize and optimize the operation process and distribution means of radioactive seed implantation technology, and better promote 125I radioactive seed implantation technology.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer
AU  - Xinxin Duan
AU  - Liuyi Yang
AU  - Jie Zhou
AU  - Ting Xiong
AU  - Aixia Sui
Y1  - 2022/06/27
PY  - 2022
N1  - https://doi.org/10.11648/j.crj.20221002.14
DO  - 10.11648/j.crj.20221002.14
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 38
EP  - 45
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20221002.14
AB  - Pancreatic cancer is a digestive system tumor with high degree of malignancy. At present, systemic chemotherapy is the main treatment method. However, due to the difficulty in early diagnosis and easy spread of pancreatic cancer, the survival cycle of patients is short and the treatment effect is poor. 125I seed brachytherapy has obvious advantages in the treatment of malignant tumors, and has been widely used in the treatment of unresectable pancreatic cancer. Either used alone or combined with chemotherapy, the treatment of 125I seed brachytherapy can effectively relieve pain, improve life quality and prolong survival. However, there are few reports about the application status. This article reviews the current updates of 125I seed brachytherapy for resectable pancreatic cancer, and expounds the application status of 125I seeds brachytherapy in combination with monotherapy chemotherapy, dual drug chemotherapy, targeted therapy, immunity therapy, palliative surgery, external radiotherapy and traditional Chinese medicine. Based on the retrospective review, future directions of research and development of brachytherapy for unresectable pancreatic cancer is also proposed, to provide better treatment care for pancreatic cancer patients. At present, there are still many problems to be solved, such as formulating the principles and standards for the application of radioactive particle implantation in the comprehensive treatment of pancreatic cancer; We will continue to standardize and optimize the operation process and distribution means of radioactive seed implantation technology, and better promote 125I radioactive seed implantation technology.
VL  - 10
IS  - 2
ER  -

Copy | Download

Author Information

Xinxin Duan

Graduate School, North China University of Science and Technology, Tangshan, China
Liuyi Yang

Graduate School, North China University of Science and Technology, Tangshan, China
Jie Zhou

Graduate School, North China University of Science and Technology, Tangshan, China
Ting Xiong

Graduate School, North China University of Science and Technology, Tangshan, China
Aixia Sui

Department of Oncology, Hebei General Hospital, Shijiazhuang, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Xinxin Duan, Liuyi Yang, Jie Zhou, Ting Xiong, Aixia Sui. (2022). Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer. Cancer Research Journal, 10(2), 38-45. https://doi.org/10.11648/j.crj.20221002.14

Copy | Download

ACS Style

Xinxin Duan; Liuyi Yang; Jie Zhou; Ting Xiong; Aixia Sui. Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer. Cancer Res. J. 2022, 10(2), 38-45. doi: 10.11648/j.crj.20221002.14

Copy | Download

AMA Style

Xinxin Duan, Liuyi Yang, Jie Zhou, Ting Xiong, Aixia Sui. Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer. Cancer Res J. 2022;10(2):38-45. doi: 10.11648/j.crj.20221002.14

Copy | Download

@article{10.11648/j.crj.20221002.14,
  author = {Xinxin Duan and Liuyi Yang and Jie Zhou and Ting Xiong and Aixia Sui},
  title = {Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer},
  journal = {Cancer Research Journal},
  volume = {10},
  number = {2},
  pages = {38-45},
  doi = {10.11648/j.crj.20221002.14},
  url = {https://doi.org/10.11648/j.crj.20221002.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221002.14},
  abstract = {Pancreatic cancer is a digestive system tumor with high degree of malignancy. At present, systemic chemotherapy is the main treatment method. However, due to the difficulty in early diagnosis and easy spread of pancreatic cancer, the survival cycle of patients is short and the treatment effect is poor. 125I seed brachytherapy has obvious advantages in the treatment of malignant tumors, and has been widely used in the treatment of unresectable pancreatic cancer. Either used alone or combined with chemotherapy, the treatment of 125I seed brachytherapy can effectively relieve pain, improve life quality and prolong survival. However, there are few reports about the application status. This article reviews the current updates of 125I seed brachytherapy for resectable pancreatic cancer, and expounds the application status of 125I seeds brachytherapy in combination with monotherapy chemotherapy, dual drug chemotherapy, targeted therapy, immunity therapy, palliative surgery, external radiotherapy and traditional Chinese medicine. Based on the retrospective review, future directions of research and development of brachytherapy for unresectable pancreatic cancer is also proposed, to provide better treatment care for pancreatic cancer patients. At present, there are still many problems to be solved, such as formulating the principles and standards for the application of radioactive particle implantation in the comprehensive treatment of pancreatic cancer; We will continue to standardize and optimize the operation process and distribution means of radioactive seed implantation technology, and better promote 125I radioactive seed implantation technology.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Application and Research Status of 125I Seeds Brachytherapy in Unresectable Pancreatic Cancer
AU  - Xinxin Duan
AU  - Liuyi Yang
AU  - Jie Zhou
AU  - Ting Xiong
AU  - Aixia Sui
Y1  - 2022/06/27
PY  - 2022
N1  - https://doi.org/10.11648/j.crj.20221002.14
DO  - 10.11648/j.crj.20221002.14
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 38
EP  - 45
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20221002.14
AB  - Pancreatic cancer is a digestive system tumor with high degree of malignancy. At present, systemic chemotherapy is the main treatment method. However, due to the difficulty in early diagnosis and easy spread of pancreatic cancer, the survival cycle of patients is short and the treatment effect is poor. 125I seed brachytherapy has obvious advantages in the treatment of malignant tumors, and has been widely used in the treatment of unresectable pancreatic cancer. Either used alone or combined with chemotherapy, the treatment of 125I seed brachytherapy can effectively relieve pain, improve life quality and prolong survival. However, there are few reports about the application status. This article reviews the current updates of 125I seed brachytherapy for resectable pancreatic cancer, and expounds the application status of 125I seeds brachytherapy in combination with monotherapy chemotherapy, dual drug chemotherapy, targeted therapy, immunity therapy, palliative surgery, external radiotherapy and traditional Chinese medicine. Based on the retrospective review, future directions of research and development of brachytherapy for unresectable pancreatic cancer is also proposed, to provide better treatment care for pancreatic cancer patients. At present, there are still many problems to be solved, such as formulating the principles and standards for the application of radioactive particle implantation in the comprehensive treatment of pancreatic cancer; We will continue to standardize and optimize the operation process and distribution means of radioactive seed implantation technology, and better promote 125I radioactive seed implantation technology.
VL  - 10
IS  - 2
ER  -

Copy | Download